Samantha Budd Haeberlein PhD

Samantha Budd Haeberlein, Ph.D., the vice president and head of Alzheimer’s Disease, Dementia, and Movement Disorders in Late-Stage Clinical Development at Biogen spoke with NeurologyLive at the Alzheimer’s Association International Conference held in Chicago, Illinois, about the TANGO II trial in Alzheimer disease.

She also noted that the dive into biomarkers to better understand which patients might respond best to BIIB092 is an entirely new area of interest for Biogen. Heberlein also discussed how in phase I, the therapy bound itself to tau proteins, reducing the tau levels by a significant amount in the cerebral spinal fluid, a promising sign as it moves into larger and later phase testing.